Triprolidine, pseudoephedrine, and codeine and Zydelig

• Generic Name: codeine / pseudoephedrine / triprolidine
• Dosage Forms: n.a.
• Other Brand Names:

Triprolidine, pseudoephedrine, and codeine combination is used to relieve cough, sneezing, itchy or runny nose, and nasal congestion (stuffy nose) caused by allergies or the common cold.

Triprolidine is an antihistamine that works by preventing the effects of a substance called histamine, which is produced by the body. Histamine can cause itching, sneezing, runny nose, and watery eyes. Pseudoephedrine is a decongestant, which decreases nasal congestion by narrowing the blood vessels and reducing blood flow to the nasal passage. Codeine is a narcotic antitussive (cough suppressant). It acts directly on the cough center in the brain to relieve cough.

When codeine is used for a long time, it may become habit-forming, causing mental or physical dependence. However, people who have continuing cough and nasal congestion should not let the fear of dependence keep them from using narcotics to relieve their cough. Mental dependence (addiction) is not likely to occur when narcotics are used for this purpose. Physical dependence may lead to withdrawal side effects if treatment is stopped suddenly. However, severe withdrawal side effects can usually be prevented by gradually reducing the dose over a period of time before treatment is stopped completely.

Triprolidine, pseudoephedrine, and codeine is available only with your doctor's prescription.

• Generic Name: idelalisib
• Dosage Forms: tablet, film coated
• Other Brand Names: Zydelig

Zydelig (idelalisib) is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Zydelig is used together with rituximab (Rituxan) to treat chronic lymphocytic leukemia, and certain types of lymphoma.

Zydelig is given after other cancer treatments did not work or have stopped working.

Zydelig was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to this medicine, but further studies are needed.